Examining Cancer Patients' Perceptions of the Impact of COVID-19 on Teleoncology: Findings From 15 Nigerian Outpatient Cancer Clinics Authors: Adedayo Joseph, Abdul R Shour, Nwamaka N Lasebikan, Mutiu A Jimoh, Bolanle C Adegboyega, Emmanuella Nwachukwu, Opeyemi Awofeso, Azeezat Ajose, Abiola Ibraheem, Omolara Aminat Fatiregun, Musa Ali-Gombe, Usman M Aliyu, Abdallah Elsaid Kotkat, Olusegun Abayomi Biyi-Olutunde, Evaristus Oseiwe Oboh, Ismail H Zubairu, Mohammad Rifat Haider, Bankole Olatosi, David Puthoff, Adedayo A Onitilo Published: 2023 ABSTRACT AbstractPURPOSETo examine cancer patients' perspectives on the impact of COVID-19 on teleoncology in Nigeria.METHODSData from a multicenter survey conducted at 15 outpatient clinics to 1,097 patients with cancer from April and July 2020 were analyzed. The study outcome was telemedicine, defined as patients who reported their routine follow-up visits were converted to virtual visits because of COVID-19 (coded yes/no). Covariates included patient age, ethnicity, marital status, income, cancer treatment, service disruption, and cancer diagnosis/type. Stata/SE.v.17 (StataCorp, College Station, TX) was used to perform chi-square and logistic regression analyses. P values ≤ .05 were considered statistically significant.RESULTSThe majority of the 1,097 patients with cancer were female (65.7%) and age 55 years and older (35.0%). Because of COVID-19, 12.6% of patients' routine follow-ups were converted to virtual visits. More patients who canceled/postponed surgery (17.7% v 7.5%; P ≤ .001), radiotherapy (16.9% v 5.3%; P ≤ .001), and chemotherapy (22.8% v 8.5%; P ≤ .001), injection chemotherapy (20.6% v 8.7%; P ≤ .001) and those who reported being seen less by their doctor/nurse (60.3% v 11.4%; P ≤ .001) reported more follow-up conversions to virtual visits. In multivariate analyses, patients seen less by their doctors/nurses were 14.3 times more likely to have their routine follow-ups converted to virtual visits than those who did not (odds ratio, 14.33; 95% CI, 8.36 to 24.58).CONCLUSIONCOVID-19 caused many patients with cancer in Nigeria to convert visits to a virtual format. These conversions were more common in patients whose surgery, radiotherapy, chemotherapy, and injection chemotherapy treatments were canceled or postponed. Our findings suggest how COVID-19 affects cancer treatment services and the importance of collecting teleoncological care data in Nigeria. BACKGROUND COVID-191-3 first emerged in Wuhan, China, in December 2019, quickly spreading in 215 countries,1,4-6 and it (and its variants) was still spreading at the time of writing this manuscript. Ever since it has caused significant disruption to health care systems worldwide,5 causing significant loss of life, disrupting livelihood, and jeopardizing recent advances toward health and sustainability goals.7 CONTEXT Key Objective Key Objective Teleoncology care was used during the COVID-19 pandemic to reduce infection risks, costs, and wait times. Although telemedicine has benefits, data on how COVID-19 affected the telemedicine experience of patients with cancer in low- and middle-income countries are limited. Our study, which looked at Nigerian cancer patients' perspectives on COVID-19's telemedicine impact, helps to fill this knowledge gap by examining cancer patients' perspectives on the impact of COVID-19 on teleoncology in Nigeria. Teleoncology care was used during the COVID-19 pandemic to reduce infection risks, costs, and wait times. Although telemedicine has benefits, data on how COVID-19 affected the telemedicine experience of patients with cancer in low- and middle-income countries are limited. Our study, which looked at Nigerian cancer patients' perspectives on COVID-19's telemedicine impact, helps to fill this knowledge gap by examining cancer patients' perspectives on the impact of COVID-19 on teleoncology in Nigeria. Knowledge Generated Knowledge Generated We discovered a 12.6% conversion rate of routine follow-ups to virtual visits in the context of relatively low telemedicine accessibility before the pandemic. These conversions were more common in patients whose surgery, radiotherapy, chemotherapy, and injection chemotherapy treatments had been delayed as a result of COVID-19. We discovered a 12.6% conversion rate of routine follow-ups to virtual visits in the context of relatively low telemedicine accessibility before the pandemic. These conversions were more common in patients whose surgery, radiotherapy, chemotherapy, and injection chemotherapy treatments had been delayed as a result of COVID-19. Relevance Relevance Our findings suggest how COVID-19 affects cancer treatment services and the importance of collecting teleoncological care data in Nigeria, providing important information informing efficiency and resource allocation in resource-constrained countries. Our findings suggest how COVID-19 affects cancer treatment services and the importance of collecting teleoncological care data in Nigeria, providing important information informing efficiency and resource allocation in resource-constrained countries. The disease has spread regionally, with a total of 8,849,904 confirmed cases and 171,888 deaths in Africa as of May 11, 2022.8 As of that date, there were 255,766 confirmed cases in Nigeria, with 3,143 deaths.8 The first case of COVID-19 was reported in Nigeria on February 27, 2020, and the government imposed lockdown measures on March 30, 2020, in an effort to control the spread.9 The lockdown and subsequent disruption of care services have had serious consequences for a country with an underresourced health care system, which ranks 187th of 195 countries in terms of health care delivery.10 As a result, health care facilities began to adapt their treatment models to the changing environment, implementing telemedicine as a method of providing care to patients with cancer to avoid the challenges of in-person care and reduce the risk of transmission.10 Telemedicine uses remote patient monitoring via phone calls, video, or messages on mobile devices or smartphones, allowing physicians to diagnose, treat, and monitor patients without requiring a face-to-face visit.10,11 Before the onset of COVID-19, telehealth had been studied in a number of countries.10,12 The benefits of telehealth include reduction of in-person visits, narrowing of in-person care to those who require urgent services, mitigation of personal protective equipment shortages through virtual ward rounds, reduction of costs and waiting times, and reduction of risk of COVID-19 infection among cancer care providers.10 Telemedicine has also been proposed as part of a strategy to address health inequality in the health care industry.12 Many studies have found significant differences in COVID response between high-income countries and low- and middle-income countries (LMICs) such as Nigeria, and some studies have reported that patients with preexisting conditions including cancer have higher mortality rates for COVID-19.13,14 These disparities in care carry significant consequences, with reports of a cancer care backlog, and, even in high-income countries such as the United Kingdom and the United States, the possibility of increased death due to delayed care and COVID-19 infection among patients with cancer.15 However, these disparities can be mitigated by offering telemedicine services, which have been successful in providing patients with cancer with symptom management, chemotherapy supervision, psychosocial support, survivorship care, and palliative care.16 Telemedicine has also been proposed as part of a global strategy to address health disparities, inequality, and brain drain in the health care industry.12 During the COVID-19 pandemic, oncology care adopted telehealth services (teleoncology) out of necessity. Given the growing popularity of telemedicine, one recent study17 suggested further research into current patient perceptions. Our study fills this knowledge gap by examining cancer patient's perspectives regarding COVID-19's impact on telemedicine in Nigeria. Although telemedicine has some clear benefits from a provider's perspective,17 data from the patient perspective, especially in LMICs such as Nigeria, have remained limited. By collecting and analyzing such data, our study informs cancer preventative and treatment strategies; positive patient perception of telemedicine could facilitate the adoption of services beyond the COVID era and serve to improve cancer care delivery in the country and other LMICs.11 The knowledge gained in this study focuses on how patients with cancer in Nigeria experienced telemedicine during the COVID-19 pandemic, how they benefitted from telemedicine services, and how collecting telemedicine-related cancer care data in this LMIC can affect other health contexts. METHODS Data and Population We analyzed data from a multicenter survey including 1,097 patients with cancer between April and July 2020 (Data Supplement). This cross-sectional study was conducted in 15 centers in Nigeria's three major geopolitical zones: north, south, and west described in a recent article.18 These centers care for approximately 70% of all patients with cancer in Nigeria.18 The National Health Research and Ethics Committee of Nigeria granted Institutional Review Board approval for the study. The data collection process, study area, study design, and consent process were all thoroughly described in a recent article.18 This was a multi-institutional cross-sectional study that used a self-report questionnaire. The study area included government-funded and privately-funded cancer treatment centers throughout Nigeria's geopolitical regions as described in this article.18 Participants in this study were chosen on the basis of specific characteristics of interest (cancer) encountered in the clinic, considering the challenges posed by the COVID-19 pandemic. Our researchers recorded the information present in this cancer population using a questionnaire, which allowed researchers to look at multiple factors at once (age, income, sex, etc). This type of study has several advantages, including lower costs and efficiency in a fast-paced, difficult cancer environment, allowing researchers to acquire a large amount of data efficiently. Although this study design may result in reporting bias and cannot be used to determine causal correlations, it served as a useful springboard for future research attempting to inform causality. In terms of sample size calculation, we used a consecutive sampling of patients between April and July 2020. All patients who were seen at the centers during the study period, who met the eligibility criteria and willingly consented to participate, were included. A minimum sample size of 422 was projected using the Cochran formula for cross-sectional surveys, and a presumed prevalence of 50% was used in the sample size calculation.19,20 Inclusion criteria were all patients with histologically confirmed cancer, regardless of type, patients age ≥ 18 years, and eligible participants who consent to the study. Unstable patients presenting with acute illnesses or emergency complications and non–English-speaking patients who are unable to read and write were excluded. Study Measures The study's dependent variable was telemedicine use. The survey question given to patients was “have your routine follow-up visits been converted to virtual visits (phone call or video)?” Patients gave a yes/no response. Covariates were conceptualized and selected using Anderson's Model of Health Service Utilization21 including three dynamics influencing health care utilization: predisposing factors, enabling factors, and need.21 Predisposing factors included the patient's sex (coded as male and female), age (18-34, 35-44, 45-54, and 55 years and older), religion (Christianity and Islam), ethnicity (Hausa, Igbo, Yoruba, and Other), and marital status (married, single, and divorced/separated/widowed). Enabling factors were education level (none, primary, secondary, and tertiary), occupation type (business, civil/public servant, retired, other (clergy, health worker), monthly income in Naira and US dollars using April 24, 2022 exchange rate, grouped as < N40,000 (< $96); N40,000-< N200,000 ($96-<$480); N200,000 and above (≥ $480). Need factors included cancer diagnosis/type (breast cancer, head and neck cancers, gynecologic cancer (cervical, endometrial, and ovarian), male monoclonal gammopathy of unknown significance (bladder, prostate, and testicular), and others (central nervous system, sarcomas, skin, lymphomas etc). Need factors also included cancer treatment received (surgery, chemotherapy, radiotherapy, and chemoradiation), comorbidities (hypertension, diabetes, and asthma/chronic obstructive pulmonary disease), and impact of COVID-19 on cancer care (canceled/postponed surgery, radiotherapy, chemotherapy, injection chemotherapy, and seen less by doctor/nurse), all coded as no/yes. We also included variables on patient perceptions of teleoncology, framed as whether their virtual consultation is a good alternative to face-to-face visits, whether getting virtual consultations is financially difficult, and whether they thought their doctors and nurses can properly diagnose and treat via the virtual platform during COVID-19. All these questions were coded as no/yes. Statistical Analysis First, we provided descriptive statistics for all variables. Second, a bivariate analysis (using chi-square tests on all measures by study outcome (telemedicine use) was performed. Third, a multivariate logistic regression analysis of predisposing, enabling, and need factors by study outcome was conducted. We reported P values, odds ratios (ORs), and their 95% CIs. Stata/SE.v.17.0 (StataCorp, College Station, TX) was used for all statistical analyses, and P values ≤ .05 were considered statistically significant. RESULTS As shown in Table 1, the majority of the 1,097 patients with cancer were female (65.7%) and age 55 years and older (35.0%). Because of COVID-19, 12.6% of patients' routine follow-ups were converted to virtual visits. More patients who canceled/postponed surgery (17.7% v 7.5%; P ≤ .001), radiotherapy (16.9% v 5.3%; P ≤ .001), chemotherapy (22.8% v 8.5%; P ≤ .001), injection chemotherapy (20.6% v 8.7%; P ≤ .001), and those who reported being seen less by their doctor/nurse (60.3% v 11.4%; P ≤ .001) reported telemedicine use. TABLE 1Patient Characteristics and Perspective on the Impact of COVID-19 on Telemedicine (study outcome) in Nigeria Patient Characteristics and Perspective on the Impact of COVID-19 on Telemedicine (study outcome) in Nigeria Figure 1 depicts telemedicine access by recommendation, defined as when patients with cancer reported that telemedicine is a good alternative to face-to-face visits. More patients who used telemedicine recommended it as a good option to face-to-face appointments than those who did not (53.7% v 46.3%; P < .001). Furthermore, higher-income patients had more access to telemedicine than low-income patients (Fig 2). Patients with cancer with a monthly income of more than 40,000 Naira had greater access to telemedicine (72.8%) than those with a monthly income of < 40,000 Naira (27.2%) at P = .02. As a result of COVID-19 (Fig 3), more patients who reported being seen less frequently by a doctor/nurse (60.3%; P < .001) and those who delayed chemotherapy (22.8%; P < .001) and injection chemotherapy (20.6%; P < .001) used telemedicine more frequently. More patients with cancer who had 1-2 treatment delays (Fig 4) used telemedicine than those who had no delay or 3-5 delays (54.4% v 26.5%, 19.1%; P < .001). Access to telemedicine by recommendation (good alternative to face-face visits) among Nigerian patients with cancer, 2020 (P < .001). Access to telemedicine by monthly income among Nigerian patients with cancer in 2020 (P = .02). N, Nigerian Naira. Access to telemedicine (%) by delayed cancer treatments because of COVID-19 in Nigeria, 2020 (P < .001). Access to telemedicine by number of delayed cancer treatment because of COVID-19 in Nigeria, 2020 (P < .001). In multivariate analyses, patients seen less by their doctors/nurses were 14.3 times more likely to use telemedicine than those who did not (OR, 14.33; 95% CI, 8.36 to 24.58). Patients who used telemedicine (compared with those who did not) were 2.2 times more likely to report that virtual consultation is a good alternative to face-to-face visits during COVID-19 (OR, 2.23; 95% CI, 1.38 to 3.59). In summary, patients with cancer were largely females, age 55 years and older. Owing to COVID-19, more patients reported delaying surgery, radiation, chemotherapy, injectable chemotherapy, and seeing a doctor/nurse less frequently. More patients also reported that virtual consultations were a good alternative to face-to-face visits, that accessing virtual consultations was financially challenging, and that doctors were able to appropriately diagnose and treat via virtual platforms. Adjusted results indicate that patients' monthly income, the type of treatment they received, and the number of doctors or nurses they saw because of COVID-19 were found to be highly associated with their use of telemedicine. DISCUSSION Teleoncology care was used during the COVID-19 pandemic to reduce infection risks, costs, and wait times. Although telemedicine has benefits, data are limited regarding how COVID-19 affected the telemedicine experience of patients with cancer in LMICs. Our study, which examined Nigerian cancer patient perspectives on COVID-19's telemedicine impact, begins to fill this knowledge gap. We discovered conversion rate in the context of relatively low telemedicine accessibility before the pandemic, a 12.6% conversion of routine follow-ups to virtual visits is surprising. These conversions were more common among patients whose surgery, radiotherapy, chemotherapy, and injection chemotherapy treatments were delayed because of COVID-19. Previous studies contributed to our understanding of the effect of telehealth interventions on cancer survivors' quality of life22,23; however, they did not examine how patients with cancer perceived COVID-19's impact on their telemedicine in Nigeria. Another recent study, which looked at medical oncologists' perspectives on the barriers and benefits of telemedicine during the COVID-19 pandemic, including clinical effectiveness, access to care, and financial impact, recommended more research into existing patient perceptions on the topic.17 By using 15 of the largest cancer treatment centers across Nigeria, assessed for service interruptions experienced by patients with cancer, our research adds to the body of knowledge by determining which cancer service/treatment interruptions had a significant impact on the transition to telemedicine. A significant proportion of patients (12.6%) in our study used telemedicine as a result of COVID-19 and believed virtual consultations were a good alternative for face-to-face visits with their oncologists. Furthermore, an increase in monthly income was significantly associated with telemedicine use. These three findings are similar to the findings of Donelan et al24 who discovered 75.2% of study participants thought telehealth visits were equivalent to or better than face-to-face visits. Nearly half of the patients in our study believe their oncologists can properly diagnose and treat them through telehealth visits. This aligns with findings in studies by Yildiz et al25 and Kang et al26 in 2020, in which patients with cancer reported that telehealth visits were sufficient in meeting their needs without additional face-to-face visits. Our adjusted analysis yielded that patients whose routine follow-ups were converted to virtual visits (compared with those who did not) were 2.2 times more likely to use telemedicine. This study finding is consistent with literature showing acceptance and high levels of patient satisfaction with teleoncology.27-29 Several studies have demonstrated clinical and cost benefits of teleoncology.28 Similar assessments of the expanded use of teleoncology because of COVID-19 demonstrate that patient mean satisfaction remained relatively high after the shift.30-32 Results from other studies, although mixed, were consistent, but showed that although teleoncology was well received, patient satisfaction declined for new or worsening conditions. Considering these parameters and limited capacity (ie, trained oncologists) in LMICs, teleoncology could become an important tool increasing access to medical care for oncology patients in resource-constrained nations such as Nigeria and beyond. We further discovered that patients earning N200,000 or more per month were 2.4 times more likely to use telemedicine than patients earning less than N40,000. This discovery might corroborate the argument that financial constraints affect access to health care, even in the virtual setting, and it may encourage policymakers to take this into account as a budgetary request or source of government assistance for cancer patients who occupy a low-income status. This socioeconomic disparity in the utilization of telemedicine is consistent with other studies that have reported higher uptake of telemedicine among patients with higher income.33 Another contribution our study makes to the literature of teleoncology concerns how patients who use telemedicine found doctors properly diagnosed and treated them via the virtual platform. Early pandemic data demonstrate the feasibility of integrating virtual consultations into a comprehensive cancer treatment plan involving radiation treatment.26 Yildiz et al25 reported high levels of patient satisfaction with the ability of virtual consultations to adequately address clinical needs from a high-volume cancer center. Other studies have reported similar patient satisfaction with, or preference for, the convenience and protection from exposure that virtual consultations proffer.24 In our study, the choice of virtual consultations was associated with patient confidence in physician diagnostic and decision-making ability via the remote platform. Reed et al34 found certain sociodemographic factors such as age, distance from the clinic, and internet access correlate with patient choice of virtual consultation.35 However, potential areas of concern that could undermine patient satisfaction with virtual consultation also include the lack of a clinical physical examination.36 Despite this concern, patients in our study who transitioned to teleoncology found doctors able to diagnose and treat them adequately via the virtual teleoncology platform, indicating a higher satisfaction use of teleoncology. There were several limitations to this study. First, the study surveyed only patients who were seen at the clinic. This could inadvertently create a bias by excluding those who are too ill to attend clinic or unable to reach the clinic for geographic or other reasons. This could mean that patients who were most affected by the pandemic were least surveyed. To overcome this, the study recruited every patient seen over as minimum duration of 4 months to allow even sick patients time to recover and return to the clinic. Other populations that would have been excluded are those who were not on active treatment at the time of the pandemic or the survey, potentially excluding those with cured or curable disease. In addition, the study population comprised a larger proportion of women compared with men. This is likely due to the fact that breast cancer is the most common adult malignancy in the country. It could, however, be an indication of male health seeking behavior that requires further investigation. The predominance of females in the study population could potentially compromise the findings and inferences with regards to male patients. The involvement of centers from all the geopolitical regions of the country is one way to ensure that males from every region were surveyed and the data representative of the wider population. Second, there is agreement, both in our survey and in the general literature, on the patient's fear of missing something important in terms of cancer screening, and telemedicine may be less accessible in higher poverty areas, potentially exacerbating existing health disparities for some populations.37,38 Finally, we analyzed data from patients with cancer at a specific point in time (2020) to better understand the determinants of teleoncology during the pandemic and to define the characteristics of the patients with cancer. However, no individuals were followed up on over time, which would have been critical in decreasing bias and giving crucial information for a deeper understanding of cancer patients' opinions on the influence of COVID-19 on teleoncology in Nigeria, as well as how COVID-19 affects cancer treatment services. Our findings have important implications for the effective implementation of telemedicine as a crucial component of the COVID-19 pandemic risk reduction plan, as suggested by local and international organizations.11 The Centers for Disease Control recommends people avoid unnecessary medical appointments and instead use alternatives to face-to-face therapy and visits.10 Similarly, a Nigerian Expert Panel discussion published in 2020 advocated for the use of telemedicine for patients with cancer on follow-up or who only require a prescription.39 At a broader scope, discussing the benefits and challenges of telemedicine for oncology patients during the height of pandemic in Nigeria provided significant information that other countries with the same socioeconomic background could relate and use. Further studies assessing telemedicine deployment in oncology from the physician perspective would be valuable to expand the body of knowledge. Combining patient-reported data with physician-reported data carries the potential to overcome unexpected barriers that may be missed by surveying only one of these two groups. Telemedicine has the potential to increase efficiency and resource allocation in resource-constrained LMICs such as Nigeria. Providing patients with the choice of physical or remote care could make a significant impact on overburdened healthcare systems. Nigerian patients with cancer had a high conversion rate of routine follow-ups to virtual visits, and these conversions were more common in patients whose surgery, radiotherapy, chemotherapy, and injection chemotherapy treatments were delayed because of COVID-19. Bolanle C. Adegboyega Employment: Lagos University Teaching Hospital Emmanuella Nwachukwu Honoraria: Sanofi, Pfizer Consulting or Advisory Role: Sanofi, Roche Travel, Accommodations, Expenses: ESMO Opeyemi Awofeso Employment: NSIA-LUTH Cancer Center No other potential conflicts of interest were reported. AUTHOR CONTRIBUTIONS Conception and design: Adedayo Joseph, Mutiu A. Jimoh, Bolanle C. Adegboyega, Emmanuella Nwachukwu, Opeyemi Awofeso, Azeezat Ajose, Abiola Ibraheem, Usman M. Aliyu, Abdallah Elsaid Kotkat, Olusegun Abayomi Biyi-Olutunde, Mohammad Rifat Haider, Bankole Olatosi, Adedayo A. Onitilo Financial support: Adedayo Joseph, Mutiu A. Jimoh, Olusegun Abayomi Biyi-Olutunde Administrative support: Adedayo Joseph, Mutiu A. Jimoh, Bolanle C. Adegboyega, Azeezat Ajose, Olusegun Abayomi Biyi-Olutunde Provision of study materials or patients: All authors Collection and assembly of data: Adedayo Joseph, Nwamaka N. Lasebikan, Mutiu A. Jimoh, Bolanle C. Adegboyega, Emmanuella Nwachukwu, Opeyemi Awofeso, Abiola Ibraheem, Omolara Aminat Fatiregun, Musa Ali-Gombe, Usman M. Aliyu, Olusegun Abayomi Biyi-Olutunde, Evaristus Oseiwe Oboh, Ismail H. Zubairu, Adedayo A. Onitilo Data analysis and interpretation: Adedayo Joseph, Abdul R. Shour, Nwamaka N. Lasebikan, Emmanuella Nwachukwu, Opeyemi Awofeso, Abiola Ibraheem, Usman M. Aliyu, Olusegun Abayomi Biyi-Olutunde, David Puthoff, Adedayo A. Onitilo Manuscript writing: All authors Final approval of manuscript: All authors Accountable for all aspects of the work: All authors AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Bolanle C. Adegboyega Employment: Lagos University Teaching Hospital Emmanuella Nwachukwu Honoraria: Sanofi, Pfizer Consulting or Advisory Role: Sanofi, Roche Travel, Accommodations, Expenses: ESMO Opeyemi Awofeso Employment: NSIA-LUTH Cancer Center No other potential conflicts of interest were reported. REFERENCES